Literature DB >> 11259648

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

L Hanus1, S Abu-Lafi, E Fride, A Breuer, Z Vogel, D E Shalev, I Kustanovich, R Mechoulam.   

Abstract

Two types of endogenous cannabinoid-receptor agonists have been identified thus far. They are the ethanolamides of polyunsaturated fatty acids--arachidonoyl ethanolamide (anandamide) is the best known compound in the amide series--and 2-arachidonoyl glycerol, the only known endocannabinoid in the ester series. We report now an example of a third, ether-type endocannabinoid, 2-arachidonyl glyceryl ether (noladin ether), isolated from porcine brain. The structure of noladin ether was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and was confirmed by comparison with a synthetic sample. It binds to the CB(1) cannabinoid receptor (K(i) = 21.2 +/- 0.5 nM) and causes sedation, hypothermia, intestinal immobility, and mild antinociception in mice. It binds weakly to the CB(2) receptor (K(i) > 3 microM).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259648      PMCID: PMC31108          DOI: 10.1073/pnas.061029898

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Miltefosine--the long-awaited therapy for visceral leishmaniasis?

Authors:  B L Herwaldt
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245

2.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

3.  Synthesis and biological activities of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, and its metabolically stable ether-linked analogues.

Authors:  Y Suhara; H Takayama; S Nakane; T Miyashita; K Waku; T Sugiura
Journal:  Chem Pharm Bull (Tokyo)       Date:  2000-07       Impact factor: 1.645

4.  Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines.

Authors:  S M Konstantinov; M R Berger
Journal:  Cancer Lett       Date:  1999-10-01       Impact factor: 8.679

Review 5.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

6.  Glyceryl ethers in peroxisomal disease.

Authors:  A Poulos; A Bankier; K Beckman; D Johnson; E F Robertson; P Sharp; L Sheffield; H Singh; S Usher; G Wise
Journal:  Clin Genet       Date:  1991-01       Impact factor: 4.438

7.  The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  1972-12       Impact factor: 8.739

8.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

9.  Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.

Authors:  E Fride; R Mechoulam
Journal:  Eur J Pharmacol       Date:  1993-02-09       Impact factor: 4.432

10.  A novel probe for the cannabinoid receptor.

Authors:  W A Devane; A Breuer; T Sheskin; T U Järbe; M S Eisen; R Mechoulam
Journal:  J Med Chem       Date:  1992-05-29       Impact factor: 7.446

View more
  161 in total

Review 1.  Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice.

Authors:  G Kunos; S Bátkai
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.

Authors:  Guanglin Kuang; Guoping Hu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-09       Impact factor: 1.810

Review 3.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 4.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

Review 5.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

6.  Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.

Authors:  E K Jones; T C Kirkham
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 8.  Lipidomic analysis of endocannabinoid metabolism in biological samples.

Authors:  Giuseppe Astarita; Daniele Piomelli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-01-14       Impact factor: 3.205

Review 9.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

10.  Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.

Authors:  Eberhard Schlicker; Agnes Redmer; Andre Werner; Markus Kathmann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.